GSK-256066

DB12137InvestigationalSmall molecule

Gsk256066 has been used in trials studying the treatment and diagnostic of SAR, Asthma, Mild Asthma, Allergic Rhinitis, and Seasonal Allergic Rhinitis, among others.

Mechanism: Pharmacologically active on Phosphodiesterase 4
Curator reviewed
Formula / weight: C₂₇H₂₆N₄O₅S · 518.584 g/mol (avg)
Code names: GSK-256066

Resolves to

Compound

UNII2D6GK059SRCAS801312-28-7ChEMBLCHEMBL570015PubChem9827968

Structure

InChIKeyJFHROPTYMMSOLG-UHFFFAOYSA-NSMILESCOC1=CC=CC(NC2=C(C=NC3=C(C)C=C(C=C23)S(=O)(=O)C2=CC(=CC=C2)C(=O)N(C)C)C(N)=O)=C1

Targets

P27815PDE4A

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Drug interactionStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with GSK-256066, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account